Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 58.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 52,328 shares of the biopharmaceutical company’s stock after selling 72,708 shares during the quarter. Handelsbanken Fonder AB’s holdings in Regeneron Pharmaceuticals were worth $32,629,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. WPG Advisers LLC increased its stake in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the last quarter. SHP Wealth Management purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $26,000. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $29,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.4%

NASDAQ REGN opened at $797.00 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The stock has a market capitalization of $82.06 billion, a P/E ratio of 19.70, a PEG ratio of 1.37 and a beta of 0.22. The firm’s 50-day moving average is $665.31 and its two-hundred day moving average is $713.04. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the business earned $12.81 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Leerink Partners reaffirmed a “market perform” rating and set a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $797.75.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, signaling continued confidence in the company’s business and pipeline prospects. Goldman Sachs Keeps Their Buy Rating on Regeneron
• Positive Sentiment: Recent analysis highlighted continued strength in Eylea HD and Dupixent, along with oncology growth and pipeline progress. The stock has risen 21.9% over the past month, although the sharp advance may also increase profit-taking risk. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
• Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio, but the figures also contain an undefined percentage change and appear unreliable. Consequently, the data provides no meaningful indication of short-covering or bearish positioning.
• Negative Sentiment: Several law firms, including Pomerantz, Gross, Faruqi & Faruqi, and Hagens Berman, are promoting or reminding investors about a securities class action against Regeneron. The litigation follows disclosures that a Phase 3 melanoma therapy trial failed, an event reportedly associated with an approximately $11 billion market-capitalization loss. The legal notices themselves do not establish wrongdoing, but they add reputational and potential financial-risk concerns. Investors covered by the proposed class period may face a September 14, 2026 lead-plaintiff deadline. REGN Investor Alert

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.